These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 15478074)

  • 21. Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden.
    Bonnet MM; Pinoges LL; Varaine FF; Oberhauser BB; O'Brien DD; Kebede YY; Hewison CC; Zachariah RR; Ferradini LL
    AIDS; 2006 Jun; 20(9):1275-9. PubMed ID: 16816556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.
    Loubiere S; el Filal KM; Sodqi M; Loundou A; Luchini S; Cleary S; Moatti JP; Himmich H
    Antivir Ther; 2008; 13(2):241-51. PubMed ID: 18505175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
    Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous HAART improves survival in children coinfected with HIV and TB.
    Pensi T; Hemal A; Banerjee T
    Trop Med Int Health; 2012 Jan; 17(1):52-8. PubMed ID: 21967134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of anti-tuberculosis treatment among patients receiving highly active antiretroviral therapy at Vihiga district hospital in 2007.
    Kwange SO; Budambula NL
    Indian J Med Microbiol; 2010; 28(1):21-5. PubMed ID: 20061758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of highly active antiretroviral therapy (HAART) used concomitantly with rifampicin in patients with tuberculosis and AIDS.
    Sant'Anna FM; Velasque L; Costa MJ; Schmaltz CA; Morgado MG; Lourenço MC; Grinsztejn B; Rolla VC
    Braz J Infect Dis; 2009 Oct; 13(5):362-6. PubMed ID: 20428637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
    Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
    J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement in CD 4 counts in HIV positive patients treated with HAART and antitubercular drugs: an observational study from North India.
    Sharma A; Wanchu A; Bansal V; Singh S; Varma S
    Indian J Pathol Microbiol; 2007 Oct; 50(4):905-7. PubMed ID: 18306602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients.
    Zhang ZN; Shang H; Jiang YJ; Liu J; Dai D; Diao YY; Geng WQ; Jin X; Wang YN
    Chin Med J (Engl); 2006 Dec; 119(23):1966-71. PubMed ID: 17199940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
    Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
    J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-associated extrapulmonary tuberculosis in Thailand: epidemiology and risk factors for death.
    Kingkaew N; Sangtong B; Amnuaiphon W; Jongpaibulpatana J; Mankatittham W; Akksilp S; Sirinak C; Nateniyom S; Burapat C; Kittikraisak W; Monkongdee P; Varma JK
    Int J Infect Dis; 2009 Nov; 13(6):722-9. PubMed ID: 19196530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-related mortality among tuberculosis patients in The Netherlands, 1993-2001.
    Haar CH; Cobelens FG; Kalisvaart NA; van Gerven PJ; van der Have JJ
    Int J Tuberc Lung Dis; 2007 Sep; 11(9):1038-41. PubMed ID: 17918662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status.
    Kwara A; Flanigan TP; Carter EJ
    Int J Tuberc Lung Dis; 2005 Mar; 9(3):248-57. PubMed ID: 15786886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
    Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
    Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-HAART tuberculosis in adults and adolescents with HIV in India: incidence, clinical and immunological profile.
    Rajasekaran S; Raja K; Jeyaseelan L; Vijilat S; Priya K; Mohan K; Parvez A; Mahilmaran A; Chandrasekar C
    Indian J Tuberc; 2009 Apr; 56(2):69-76. PubMed ID: 19810588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.